Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials

Tofacitinib Efficacy/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2/3 Trials

Abstract Introduction We assessed tofacitinib efficacy and safety in ankylosing spondylitis (AS) by body mass index (BMI) category. Methods Data were pooled from phase 2/3 trials; analyses included patients with active AS randomized (1:1) to tofacitinib 5 mg twice daily or placebo, who were stratifi...

Full description

Saved in:
Bibliographic Details
Main Authors: Hillary Norton, Paula Sliwinska-Stanczyk, Tomas Hala, Bassel El-Zorkany, Lori Stockert, Rajiv Mundayat, Lisy Wang, Christopher T. Ritchlin
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-12-01
Series:Rheumatology and Therapy
Subjects:
Body mass index
Randomized controlled trial
Rheumatology
Therapeutics
Online Access:https://doi.org/10.1007/s40744-024-00726-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40744-024-00726-6

Similar Items